125144-04-9

Basic information

• Product Name: 1H-Pyrazole-3-carbonitrile,5-amino-(9CI)
• Synonyms: 1H-Pyrazole-3-carbonitrile,5-amino-(9CI);1H-Pyrazole-3-carbonitrile, 5-aMino-;5-AMino-1H-pyrazole-3-carbonitrile;5-Amino-3-cyano-1H-pyrazole;3-Amino-1H-pyrazole-5-carbonitrile
• CAS NO: 125144-04-9
• Molecular Formula: C₄H₄N₄
• Molecular Weight: 108.104
• Product Categories: VARIOUSAMINE
• Mol File: 125144-04-9.mol

Chemical Properties

• Boiling Point: 472.2±25.0 °C(Predicted)
• Appearance: /
• Density: 1.42±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 10.80±0.10(Predicted)
• CAS DataBase Reference: 1H-Pyrazole-3-carbonitrile,5-amino-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole-3-carbonitrile,5-amino-(9CI)(125144-04-9)
• EPA Substance Registry System: 1H-Pyrazole-3-carbonitrile,5-amino-(9CI)(125144-04-9)

Safety Data

• Hazardous Substances Data: 125144-04-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrazole-3-carbonitrile,5-amino-(9CI) is used as a key intermediate in the synthesis of various pharmaceuticals for its potential biological activities. Its unique structure and reactivity contribute to the development of new drugs with improved therapeutic properties.
Used in Agrochemical Industry:
1H-Pyrazole-3-carbonitrile,5-amino-(9CI) is utilized as a building block in the creation of agrochemicals, such as pesticides and herbicides. Its incorporation into these products enhances their effectiveness in controlling pests and weeds, thereby improving crop yields and quality.

Upstream product

• 40497-11-8 ethyl 2,3-dicyanopropanoate 
• 1204246-72-9 3-nitro-1H-pyrazol-5-carbonitrile 
• 7440-66-6 zinc 

Downstream Products

• 1204244-57-4 3-(2-(4-fluorobenzoyl)pyrrolo[2,1-f][1,2,4]|triazin-4-ylamino)-1H-pyrazole-5-carbonitrile 
• 1236182-44-7 C₁₇H₁₁N₅S 
• 1241914-85-1 3-(2-(4-fluorobenzoyl)quinazolin-4-ylamino)-1H-pyrazole-5-carbonitrile 

Relevant articles and documents

4-((1H-pyrazol-3-yl)amino)phthalazin-1(2H)-one derivatives and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient

The present invention relates to a 4-((1H-pyrazol-3-yl)amino)phthalazine-1(2H)-one derivative and a pharmaceutical composition for preventing or treating cancer containing the same as an active component. The derivative exhibits high inhibitory activity on various protein kinases, and in particular, has excellent inhibitory ability on RET proto-oncogene enzymes, and also has an excellent inhibitory effect on proliferation of medullary thyroid cancer cells and lung cancer cells expressing RET fusion genes, thereby being able to be usefully used for treating medullary thyroid cancer or lung cancer, and in particular, being able to be usefully used for treating cancer in which RET fusion genes are expressed.

Fused heterocyclic compounds and application thereof

The present invention discloses fused heterocyclic compounds as well as optical isomers, cis-trans isomers or agrochemically acceptable salts thereof and an application of a composition. The fused heterocyclic compounds have a structure shown in a formula I in the description. The fused heterocyclic compounds as well as the optical isomers, the cis-trans isomers or the agrochemically acceptable salts thereof provided by the present invention have high killing activity against agricultural and forestry pests, animal parasitic pests, sanitary pests and the like, delayed effects on invasive solenopsis invicta, and lower toxicity to environmental organisms such as apis cerana and bombyx mori.

ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF

Provided herein is a method of preventing, treating, or ameliorating one or more symptoms of an adenosine A3-mediated condition, disorder, or disease, with a compound of Formula I. Also provided herein is a method of preventing, treating, or ameliorating one or more symptoms of glaucoma or ocular hypertension. Further provided herein is a method of modulating the activity of an adenosine A3 receptor.

JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are pyrrolotriazine compounds for treatment of JAK kinase, including JAK2 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF

Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. (I).